A Phase 1 Parallel Open-Label Study of the Safety and Tolerability Pharmacokinetics and Antileukemic Activity of ASTX660 as a Single Agent and in Combination with ASTX727 in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Brief description of study

The purpose of the study is to determine the safety of ASTX660 alone and in combination with ASTX727 in patients who have acute myeloid leukemia (AML) and they are unfit for intensive chemotherapy or they have relapsed or they are unresponsive to treatment.

Clinical Study Identifier: s19-01072
ClinicalTrials.gov Identifier: NCT04155580
Principal Investigator: Mohammad Maher Abdul Hay.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.